Document:

Amendment No. 3 to License Agreement

 Exhibit 10.4 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the
confidentiality request. Omissions are designated as [***]. 
  
 AMENDMENT NO. 3 TO 
 LICENSE AGREEMENT 
  
 THIS AMENDMENT NO. 3 to License Agreement No. 651-01.LIC (“AMENDMENT NO. 3”), effective as of August 17, 2004 (the
“THIRD AMENDMENT DATE”), is entered into by and between Arizona Science & Technology Enterprises d/b/a Arizona Technology Enterprises, an Arizona limited liability company having its principal place of business at 699 S. Mill Avenue,
Tempe, AZ 85281 (“AzTE”), acting on behalf of and for THE ARIZONA BOARD OF REGENTS and ARIZONA STATE UNIVERSITY, of Tempe, Arizona (“ASU”) and SEATTLE GENETICS, INC., a corporation organized under the laws of Delaware having its
principal place of business located at 21823 30th Drive S.E., Bothell, WA 98021 (“LICENSEE”). 

 
 RECITALS 
  
 WHEREAS, ASU and SGI entered into License Agreement No. 651-01.LIC
dated as of February 3, 2000, as subsequently amended on February 18, 2000 and March 14, 2002 (collectively, the “LICENSE AGREEMENT”); 
  
 WHEREAS, the parties now wish to amend the LICENSE AGREEMENT on the terms set forth herein; 
  
 NOW THEREFORE, in consideration of the mutual covenants set forth
below, the parties amend the LICENSE AGREEMENT and otherwise agree as follows (with all capitalized terms used but not defined herein having the meanings set forth in the LICENSE AGREEMENT): 
  
 AGREEMENT 
  
 1. ASU acknowledges and agrees that ASU’s [***]. ASU acknowledges and agrees that the LICENSEE [***] with respect to
products utilizing or incorporating [***]. 
  
 2. Section 2.5 of
the LICENSE AGREEMENT is amended and restated to read in its entirety as follows: 
  
 “2.5 This Agreement and grant of license hereunder are subject to the terms and conditions contained throughout this Agreement.” 
  
 3. Section 5.1.1 of the LICENSE AGREEMENT is amended and restated to read in its entirety as follows: 
  
 “The LICENSEE shall pay to ASU the following fees:

  
 (a) Within [***] of the THIRD AMENDMENT DATE,
a [***] of [***] ($[***]). 
  
 (b) Beginning in
[***], an [***] until expiration of the last to expire of the VALID CLAIMS within ASU’s PATENT RIGHTS. For purposes of illustration, the [***] payment schedule shall be as follows: 
  
 [***] 
  
 CONFIDENTIAL 

 3. The provisions of Sections 5.2-5.14, 9.1, 9.2, 9.4 and 9.5 of the LICENSE AGREEMENT shall apply only
to [***], and not [***]. Articles 8 and 14 and Sections 5.1.3 and 5.1.4 of the LICENSE AGREEMENT are deleted in their entireties. 
  
 4. This AMENDMENT NO. 3 is effective for all purposes as of the THIRD AMENDMENT DATE. Except as otherwise expressly modified by this AMENDMENT NO. 3, the
LICENSE AGREEMENT remains in full force and effect in accordance with its terms. 
  
 5. This AMENDMENT NO. 3 may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document. 
  
 6. [***] (as defined in the LICENSE AGREEMENT) pursuant to a [***]. [***]
represents and warrants that it has all necessary power and authority to [***] in entering into this AMENDMENT NO. 3, which shall be binding and enforceable in all respects with regard to [***]. 
  
 [Signature page follows] 
  

 [***] Confidential treatment has
been requested with respect to the omitted portions. 
  

					
	Confidential	 	-2-	 	 

 IN WITNESS WHEREOF, the parties have caused this AMENDMENT NO. 3 to be executed by their respective duly
authorized officers as of the THIRD AMENDMENT DATE. 
  

			
	 SEATTLE GENETICS, INC.

		
	 By:
	 	 /s/ Clay B. Siegall

	 	 	 (Signature)

		
	 Name:
	 	 Clay B. Siegall, Ph.D.

		
	 Title:
	 	 President and Chief Executive Officer

	
	 ARIZONA SCIENCE & TECHNOLOGY
 ENTERPRISES

		
	 By:
	 	 /s/ Peter Slate

	 	 	 (Signature)

		
	 Name:
	 	 Peter Slate

		
	 Title:
	 	 Chief Executive OfficerForm of Stock Option Agreement

  
 Exhibit 10.1

  
 NMT MEDICAL, INC. 
  
 Incentive Stock Option Agreement 
 Granted Under 2001 Stock Incentive Plan, As Amended 
  

	1.	Grant of Option. 

  
 This agreement evidences the grant by NMT Medical, Inc., a Delaware corporation (the “Company”), on <<Grant Date>> (the “Grant
Date”) to [First Name] [Last Name], an employee of the Company (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s 2001 Stock Incentive Plan, as amended (the
“Plan”), a total of <<Number>> shares (the “Shares”) of common stock, $.001 par value per share, of the Company (“Common Stock”) at <<Price>> per Share. Unless earlier terminated, this option
shall expire on <<Exp. Date>> (the “Final Exercise Date”). 
  
 It is intended that the option evidenced by this agreement shall be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended and any regulations promulgated there under (the
“Code”). Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms. 
  

	2.	Vesting Schedule. 

  
 This option will become exercisable (“vest”) <<Vesting Schedule>>. 
  
 The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum
extent permissible it shall continue to be exercisable, in whole or in part, with respect to all shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.

  
 <<In the event of an Acquisition Event (as defined in
the Plan), and as long as the Participant is an employee, officer, director, consultant or advisor of the Company at such time, this option shall become immediately exercisable in full. An “Acquisition Event” is defined in the Plan to mean
(a) any merger or consolidation of the Company with or into another entity as a result of which the Common Stock is converted into or exchanged for the right to receive cash, securities or other property or (b) any exchange of shares of the Company
for cash, securities or other property pursuant to a statutory share exchange transaction>>. <<Optional provision depending on grant>> 
  

	3.	Exercise of Option 

  

	 	(a)	Form of Exercise. Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company at its principal office, accompanied by
this agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.

  

 -1- 

	 	(b)	Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or
she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the Company or any parent or subsidiary of the Company as defined in Section 424(e) or (f) of the Code
(an “Eligible Participant”). 

  

	 	(c)	Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e)
below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent that the Participant was
entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract,
confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation. 

  

	 	(d)	Exercise Period Upon Death or Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date
while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or
disability of the Participant by the Participant, provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided
that this option shall not be exercisable after the Final Exercise Date. 

  

	 	(e)	Discharge for Cause. If the Participant, prior to the Final Exercise Date, is discharged by the Company for “cause” (as defined below), the right to exercise this
option shall terminate immediately upon the effective date of such discharge. “Cause” shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including,
without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which
determination shall be conclusive. The Participant shall be considered to have been discharged for “Cause” if the Company determines, within 30 days after the Participant’s resignation, that discharge for cause was warranted.

  

	4.	Withholding. 

  
 No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to
the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option. 
  

	5.	Nontransferability of Option. 

  
 This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except
by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 
  

 -2- 

	6.	Disqualifying Disposition. 

  
 If the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one year after such Shares were
acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition. 
  

	7.	Provisions of the Plan. 

  
 This option is subject to the provisions of the Plan, a copy of which is available to the Participant at any time by written or verbal request.

  
 IN WITNESS WHEREOF, the Company has caused this option, (dated
<<Grant Date>>), to be executed under its corporate seal by its duly authorized officer. This option shall take effect as a sealed instrument. 
  

			
	 NMT Medical, Inc.

		
	 By:
	 	 
	 	 	 Name:

	 	 	 Title:

  
 PARTICIPANT’S ACCEPTANCE 
  
 The undersigned hereby
accepts the foregoing option, (dated <<Grant Date>>), and agrees to the terms and conditions thereof. The undersigned hereby acknowledges that they have the right to review a copy of the Company’s 2001 Stock Incentive Plan,
as amended. 
  

			
	 PARTICIPANT:

	
	 
		
	 Address: 
	 	 
		
	 	 	 

  
 Grant dated, (<<Grant
Date>>), for [First Name] [Last Name] 
  

 -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]